Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone

Lissoni, Paolo; Barni, Sandro; Meregalli, S.; Fossati, V.; Cazzaniga, M.; Esposti, D.; Tancini, G

doi:10.1038/bjc.1995.164

Cited by 135 publications

(99 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have demonstrated the antiproliferative role of melatonin using an MCF7 cell model to study the anti-estrogenic effect of this hormone (Hill and Blask, 1988;Wilson et al, 1992;Molis et al, 1994Molis et al, , 1995Lissoni et al, 1995). Estradiol was used in the present study to induce MCN increase in the testis to verify the effect(s) of melatonin on mast cell accumulation.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of the increased 17β-estradiol-induced mast cell number by melatonin in the testis of the frog Rana esculenta, in vivo and in vitro

Izzo

d’Istria

Serino

et al. 2004

Journal of Experimental Biology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibition of the increased 17β-estradiol-induced mast cell number by melatonin in the testis of the frog Rana esculenta, in vivo and in vitro

Izzo

d’Istria

Serino

et al. 2004

Journal of Experimental Biology

View full text Add to dashboard Cite

show abstract

“…(20) • www.malignanttumours.org пациенток [44]. Далее в рандомизированом исследовании у предлеченных пациенток с гормоннегативным РМЖ, по-лучавших тамоксифен с МЛТ, показано увеличение общей выживаемости (p<0.01) и объективных ответов на лечение (p<0.05) по сравнению с группой контроля [45].…”

Section: фундаментальная онкология и экспериментальная медицина • Fununclassified

Perspectives of Melatonin Use in Clinical Oncology

Cемиглазова¹,

Osipov²,

Novik³

et al. 2016

Zlokač. opuholi

View full text Add to dashboard Cite

Перспективы использования мелатонина в клинической онкологииPerspectives of melatonin use in clinical oncology www.malignanttumours.org • № 4 -2016 г. (20) • MALIGNANT TUMOURSАннотация В 21-м веке достигнуты значительные успехи в лекарственном лечении злокачественных опухолей. Применение новых препаратов позволяет увеличить время до прогрессирования заболевания, продолжительность жизни больных, улучшить ее качество. В последнее время активно изучается противоопухолевая активность гормона эпифиза мелатонина. Этой теме посвящены многочисленные опыты in vitro/ in vivo, в которых показана способность мелатонина тормозить злокачественный рост и потенцировать действие цитостатиков. В данном обзоре освещены данные о использовании мелатонина при лечении пациентов с солидными опухолями. Мелатонин использовался как в монотерапии, так и в комбинации с химиотерапией и иммунотерапией. Согласно результатам этих исследований применение мелатонина приводит к увеличению объективных ответов и общей выживаемости пациентов и к снижению частоты побочных эффектов химиотерапии. Однако этот гормон эпифиза до сих пор рутинно не используется в клинической онкологии и его активность следует изучать в дальнейшем в рамках рандомизированных клинических исследований. AbstractNowadays great successes have been reached in chemotherapy treatment of cancer. New medications let increase time to progression, overall survival and to improve a quality of life. Recently, antitumor activity of melatonin is actively investigated. Many in vitro/in vivo studies are devoted to this topic. In these trials was shown ability of melatonin to inhibit tumor growth and to potentiate the cytotoxic effects of chemotherapy. This review describes the use of melatonin in the treatment of patients with solid tumors. Melatonin has been used in both monotherapy and in combination with chemotherapy and immunotherapy. According to these studies, the use of melatonin increases the objective response and overall survival of patients and reduce the incidence of side effects of chemotherapy. However, this epiphyseal hormone does not routinely used in clinical oncology and will be must to investigate it in more clinical trials. УРОВНИ МЕЛАТОНИНА У БОЛЬНЫХ ЗЛОКАЧЕСТВЕННЫМИ НОВООБРАЗОВАНИЯМИС начала 40-х гг. 20-го века проводились исследования, в ходе которых выявлено, что у онкологических больных наблюдаются морфологические изменения эпифиза. Это проявляется как гипертрофией [26], так и атрофией шиш-ковидной железы [27], появлением множества кист [28,29], кальцификацией эпифиза у пациенток с раком молоч-

show abstract

“…In one study, 14 metastatic breast cancer patients who were unresponsive to tamoxifen alone were given 20 mg melatonin daily in the evening along with tamoxifen (15). A response was achieved in 28% of these patients (15). It has also been shown that melatonin increases the cytostatic antiestrogen sensitivity of tamoxifen via an unknown mechanism (3,16).…”

Section: Clinical Studies On Melatonin and Cancermentioning

confidence: 99%

“…Several clinical trials have suggested the potential of melatonin in the management of breast cancer. In one study, 14 metastatic breast cancer patients who were unresponsive to tamoxifen alone were given 20 mg melatonin daily in the evening along with tamoxifen (15). A response was achieved in 28% of these patients (15).…”

Section: Clinical Studies On Melatonin and Cancermentioning

confidence: 99%

Melatonin in Cancer Management: Progress and Promise

2006

View full text Add to dashboard Cite

Physiologic and pharmacologic concentrations of the pineal hormone melatonin have shown chemopreventive, oncostatic, and tumor inhibitory effects in a variety of in vitro and in vivo experimental models of neoplasia. Multiple mechanisms have been suggested for the biological effects of melatonin. Not only does melatonin seem to control development alone but also has the potential to increase the efficacy and decrease the side effects of chemotherapy when used in adjuvant settings. This review critically evaluates progress in the ability of melatonin to prevent or reverse cancer development and progression. We also discuss future prospects of the possible development of melatonin as a chemopreventive agent.

show abstract

Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone

Cited by 135 publications

References 10 publications

Inhibition of the increased 17β-estradiol-induced mast cell number by melatonin in the testis of the frog Rana esculenta, in vivo and in vitro

Inhibition of the increased 17β-estradiol-induced mast cell number by melatonin in the testis of the frog Rana esculenta, in vivo and in vitro

Perspectives of Melatonin Use in Clinical Oncology

Melatonin in Cancer Management: Progress and Promise

Contact Info

Product

Resources

About